All News #Library
Others
Imcyse Begins Dosing in Adaptive Phase 1/2 Trial of Imotope IMCY-0141
13 Apr 2022 //
GLOBENEWSWIRE
Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
14 Mar 2022 //
GLOBENEWSWIRE
Imcyse Reports +ve Immune Response from Phase 2 IMPACT Type 1 Diabetes Study
13 Jan 2022 //
GLOBENEWSWIRE
Imcyse appoints Gene Mack as Chief Financial Officer
08 Nov 2021 //
PHARMABIZ

Market Place
Sourcing Support